Julie B. Schweitzer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Julie B. Schweitzer has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
Clinton D. Kilts
Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, Georgia USA
2 shared publicationsJohn M. Hoffman
National Cancer Institute, National Institutes of Health, Bethesda, Maryland USA
2 shared publicationsScott T. Grafton
Center for Cognitive Sciences, Dartmouth College, Hanover, New Hampshire USA
2 shared publicationsCarole A. Kant
Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, Georgia (TKC, CAK)
1 shared publicationCaroline F. Zink
Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, Georgia USA
1 shared publicationClinton D Kilts
Maryland Psychiatric Research Center and Division of Child Psychiatry, University of Maryland School of Medicine, USA
1 shared publication
Latest Publications
- 1 October 2004
- Published by Elsevier in Biological Psychiatry
- Vol. 56 (8) , 597-606
Effect of methylphenidate on executive functioning in adults with attention-deficit/hyperactivity disorder: Normalization of behavior but not related brain activity
- 1 October 2004
- Published by Elsevier in Biological Psychiatry
- Vol. 56 (8) , 597-606
Effect of methylphenidate on executive functioning in adults with attention-deficit/hyperactivity disorder: Normalization of behavior but not related brain activity
- 6 November 2002
- Published by Springer Nature in Neuropsychopharmacology
- Vol. 28 (5) , 967-973
A Positron Emission Tomography Study Of Methylphenidate in Adults with ADHD: Alterations in Resting Blood Flow and Predicting Treatment Response
A hallmark symptom of attention-deficit hyperactivity disorder (ADHD) is an excess of motoric behavior or hyperactivity. Methylphenidate (MPH) is known to reduce hyperactivity in individuals with ADHD. Yet little is known about how it alters neural activity and how this relates to its clinical effects. The goal of this study is to examine MPH-induced changes during resting brain metabolism, and to examine how these changes correlate with measures of behavioral response to the drug. Measures of regional cerebral blood flow (rCBF) using positron emission tomography (PET) were acquired at rest for ten adult subjects with ADHD during both an unmedicated state and after a 3-week period of chronic dosing with a clinically optimal dose of MPH. Compared with the on-MPH condition, the off-MPH condition was associated with relative increases in rCBF bilaterally in the precentral gyri, left caudate nucleus, and right claustrum. The on-MPH condition was associated with relative increases in rCBF in the cerebellar vermis. A correlational analysis measured the relation between rCBF in the off-medication condition to change in ADHD ratings between the off- and on-MPH condition to identify brain regions associated with treatment response. The degree of change in the ratings was negatively correlated with rCBF increases in the midbrain, cerebellar vermis, and the precentral and middle frontal gyri in the off-MPH condition. The majority of these brain regions are involved in the planning and execution of motor behavior. These data suggest that MPH modulates brain regions associated with motor function to achieve a reduction in ADHD symptoms.
- 6 November 2002
- Published by Springer Nature in Neuropsychopharmacology
- Vol. 28 (5) , 967-973
A Positron Emission Tomography Study Of Methylphenidate in Adults with ADHD: Alterations in Resting Blood Flow and Predicting Treatment Response
A hallmark symptom of attention-deficit hyperactivity disorder (ADHD) is an excess of motoric behavior or hyperactivity. Methylphenidate (MPH) is known to reduce hyperactivity in individuals with ADHD. Yet little is known about how it alters neural activity and how this relates to its clinical effects. The goal of this study is to examine MPH-induced changes during resting brain metabolism, and to examine how these changes correlate with measures of behavioral response to the drug. Measures of regional cerebral blood flow (rCBF) using positron emission tomography (PET) were acquired at rest for ten adult subjects with ADHD during both an unmedicated state and after a 3-week period of chronic dosing with a clinically optimal dose of MPH. Compared with the on-MPH condition, the off-MPH condition was associated with relative increases in rCBF bilaterally in the precentral gyri, left caudate nucleus, and right claustrum. The on-MPH condition was associated with relative increases in rCBF in the cerebellar vermis. A correlational analysis measured the relation between rCBF in the off-medication condition to change in ADHD ratings between the off- and on-MPH condition to identify brain regions associated with treatment response. The degree of change in the ratings was negatively correlated with rCBF increases in the midbrain, cerebellar vermis, and the precentral and middle frontal gyri in the off-MPH condition. The majority of these brain regions are involved in the planning and execution of motor behavior. These data suggest that MPH modulates brain regions associated with motor function to achieve a reduction in ADHD symptoms.
- 1 August 2002
- Vol. 3 (8) , 1207-11
Drugs under investigation for attention-deficit hyperactivity disorder.
There has been substantial development of pharmacological treatments for attention-deficit hyperactivity disorder (ADHD) recently. The greatest change is the approval of new delivery systems for methylphenidate (MPH) and amphetamine (AMP) that permit once a day dosing. There are also a number of new compounds under development for the disorder, including several non-stimulant agents. These compounds target the noradrenergic, histaminergic and dopaminergic systems. The recent developments in the pharmacological treatment of ADHD should increase therapeutic options and the percentage of individuals with the disorder who can be effectively treated.
- 1 August 2002
- Vol. 3 (8) , 1207-11
Drugs under investigation for attention-deficit hyperactivity disorder.
There has been substantial development of pharmacological treatments for attention-deficit hyperactivity disorder (ADHD) recently. The greatest change is the approval of new delivery systems for methylphenidate (MPH) and amphetamine (AMP) that permit once a day dosing. There are also a number of new compounds under development for the disorder, including several non-stimulant agents. These compounds target the noradrenergic, histaminergic and dopaminergic systems. The recent developments in the pharmacological treatment of ADHD should increase therapeutic options and the percentage of individuals with the disorder who can be effectively treated.
- 1 May 2001
- Published by Elsevier in Medical Clinics of North America
- Vol. 85 (3) , 757-777
ATTENTION-DEFICIT/HYPERACTIVITY DISORDER
- 1 May 2001
- Published by Elsevier in Medical Clinics of North America
- Vol. 85 (3) , 757-777
ATTENTION-DEFICIT/HYPERACTIVITY DISORDER
- 1 February 2000
- Published by American Psychiatric Association Publishing in American Journal of Psychiatry
- Vol. 157 (2) , 278-280
Alterations in the Functional Anatomy of Working Memory in Adult Attention Deficit Hyperactivity Disorder
The authors used a functional neuroimaging study with a working memory probe to investigate the pathophysiology of attention deficit hyperactivity disorder (ADHD). Their goal was to compare regional cerebral blood flow (rCBF) changes related to working memory in adults with and without ADHD. Using [(15)O]H(2)O positron emission tomography (PET) studies, the authors compared the sites of neural activation related to working memory in six adult men diagnosed with ADHD and six healthy men without ADHD who were matched in age and general intelligence. Task-related changes in rCBF in the men without ADHD were more prominent in the frontal and temporal regions, but rCBF changes in men with ADHD were more widespread and primarily located in the occipital regions. These data suggest the use of compensatory mental and neural strategies by subjects with ADHD in response to a disrupted ability to inhibit attention to nonrelevant stimuli and the use of internalized speech to guide behavior.
- 1 February 2000
- Published by American Psychiatric Association Publishing in American Journal of Psychiatry
- Vol. 157 (2) , 278-280
Alterations in the Functional Anatomy of Working Memory in Adult Attention Deficit Hyperactivity Disorder
The authors used a functional neuroimaging study with a working memory probe to investigate the pathophysiology of attention deficit hyperactivity disorder (ADHD). Their goal was to compare regional cerebral blood flow (rCBF) changes related to working memory in adults with and without ADHD. Using [(15)O]H(2)O positron emission tomography (PET) studies, the authors compared the sites of neural activation related to working memory in six adult men diagnosed with ADHD and six healthy men without ADHD who were matched in age and general intelligence. Task-related changes in rCBF in the men without ADHD were more prominent in the frontal and temporal regions, but rCBF changes in men with ADHD were more widespread and primarily located in the occipital regions. These data suggest the use of compensatory mental and neural strategies by subjects with ADHD in response to a disrupted ability to inhibit attention to nonrelevant stimuli and the use of internalized speech to guide behavior.